July 31, 2000
AMERIPATH, INC. ANNOUNCES THE GRAND OPENING OF THE CENTER FOR ADVANCED DIAGNOSTICS

Riviera Beach, FL, July 31, 2000 – AmeriPath, Inc. (Nasdaq: PATH), the largest physician and laboratory company focused on providing anatomic pathology cancer diagnostic and healthcare information services, today announced the grand opening of its new diagnostic facility called The Center For Advanced Diagnostics (“CAD”), focusing on the detection and diagnosis of cancers. The Center offers a full array of diagnostics for hematopoietic and solid tissue malignancies, including molecular genetics, cytogenetics, flow cytometry, specialized immunohistochemistry, and minimal residual disease detection.

CAD’s staff includes multiple doctoral scientists with extensive experience and reputations in molecular genetics, cytogenetics, flow cytometry, and pathology. Pathologists, board certified in anatomic and clinical pathology, with subspecialty expertise in hematopathology, cytopathology, and solid tumor diagnosis complete the medical and scientific staff. In addition to diagnostic testing for both AmeriPath and non-AmeriPath physicians, hospitals, and other healthcare providers, CAD will be able to perform developmental work for diagnostic manufacturers, clinical research organizations (CROs), and big pharmaceutical companies using AmeriPath’s unparalleled access to normal, abnormal, and cancerous tissues.

The Company’s Senior Vice President and Medical Director, Dennis M. Smith, Jr., M.D., stated, “As we enter the new millennium, the convergence of human genomics and AmeriPath’s strategic initiatives involving genomics, advanced cancer diagnostic testing, and information technologies mark the transformation of the Company from a physician group practice to a company acknowledged as the leading diagnostic healthcare information provider.”

AmeriPath, Inc. is the nation’s largest physician and laboratory company focused on providing anatomic pathology diagnostic and healthcare information services to physicians, hospitals, national clinical laboratories and managed care organizations. The company presently operates in 14 states and employs 301 physicians that provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

...............................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath’s actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, technology and other factors identified in AmeriPath’s filings with the Securities and Exchange Commission. SEC.